Patent Expiry

Patent/Exclusivity Expiry: YORVIPATH

November 12, 2042

Company: Ascendis Pharma A/S (ASND)
Drug: YORVIPATH

Other upcoming events for ASND

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Effi

Phase 3 ReadoutPhase 3 Topline: A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Bas

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Patent/Exclusivity Expiry: YORVIPATH — ASND Patent Expiry | BioSniper